[{"data":1,"prerenderedAt":172},["ShallowReactive",2],{"drug-ethosuximide":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":35,"contraindications":67,"warnings":77,"renal":85,"monitoring":86,"interactions":87,"review":88,"examples":90,"atc":102,"iran":104,"usApproval":132,"links":138,"populations":154},"ethosuximide",1,{"fa":7,"en":8},"اتوسوکسیماید","Ethosuximide","nervous-system",{"fa":11,"en":12},"ضدتشنج سوکسینیمید","Succinimide anticonvulsant",[14],{"name":15,"market":16},"Zarontin","US",[18,19,7],"zarontin","زارونتین",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"sol-250-5","solution","oral","250 mg \u002F 5 mL oral solution",{"amount":27,"unit":28,"perVolumeMl":29},250,"mg",5,[16],[32],{"source":33,"section":34},"fda-ethosuximide","How Supplied",[36],{"id":37,"disease":38,"label":39,"population":42,"type":46,"unit":28,"dose":47,"refs":57,"notes":60},"absence","absence-epilepsy",{"fa":40,"en":41},"صرع ابسانس — شروع: ۳ تا ۶ سال ۲۵۰ mg و ۶ سال به بالا ۵۰۰ mg در روز","Absence epilepsy — start: 3–6 y 250 mg\u002Fday; ≥6 y 500 mg\u002Fday",{"minAge":43},{"value":44,"unit":45},3,"year","ageBand",{"bands":48},[49,53],{"minAge":50,"maxAge":51,"perDose":27,"dosesPerDay":5},{"value":44,"unit":45},{"value":52,"unit":45},6,{"minAge":54,"maxAge":55,"perDose":56,"dosesPerDay":5},{"value":52,"unit":45},null,500,[58],{"source":33,"section":59},"Dosage and Administration",[61],{"text":62,"refs":65},{"fa":63,"en":64},"هر ۴ تا ۷ روز ۲۵۰ mg در روز افزایش تا کنترل. دوز بهینه بیشتر کودکان ۲۰ mg\u002Fkg\u002Fروز. بالای ۱٫۵ g در روز (در دوزهای منقسم) فقط با نظارت دقیق.","Increase by 250 mg\u002Fday every 4–7 days until controlled. Optimal for most children 20 mg\u002Fkg\u002Fday. Above 1.5 g\u002Fday (divided) only under strict supervision.",[66],{"source":33,"section":59},[68],{"id":69,"severity":70,"text":71,"refs":74},"hyper","block",{"fa":72,"en":73},"حساسیت به سوکسینیمیدها.","Hypersensitivity to succinimides.",[75],{"source":33,"section":76},"Contraindications",[78],{"text":79,"refs":82},{"fa":80,"en":81},"دیسکرازی خونی (گاهی کشنده) و ترومبوسیتوپنی ایمنی؛ شمارش خون دوره‌ای.","Blood dyscrasias (sometimes fatal) and immune thrombocytopenia; periodic blood counts.",[83],{"source":33,"section":84},"Warnings",[],[],[],{"status":89,"reviewer":55,"date":55},"unverified",[91,96],{"regimen":37,"formulation":22,"input":92,"expect":95},{"ageYears":93,"weightKg":94},4,16,{"perDose":27,"mlPerDose":29},{"regimen":37,"formulation":22,"input":97,"expect":100},{"ageYears":98,"weightKg":99},8,25,{"perDose":56,"mlPerDose":101},10,[103],"N03AD01",{"status":105,"forms":106,"refs":127},"registered",[107,111,115,119,123],{"code":108,"en":109,"fa":110},"07651","ETHOSUXIMIDE 100MG CAP","کپسول اتوسوکسیماید ۱۰۰ میلی‌گرم",{"code":112,"en":113,"fa":114},"00514","ETHOSUXIMIDE 250MG CAP","کپسول اتوسوکسیماید ۲۵۰ میلی‌گرم",{"code":116,"en":117,"fa":118},"00513","ETHOSUXIMIDE 250MG\u002F5ML 240ML SYRUP","شربت اتوسوکسیماید ۲۵۰ میلی‌گرم \u002F ۵ میلی‌لیتر ۲۴۰ میلی‌لیتر",{"code":120,"en":121,"fa":122},"52620","ETHOSUXIMIDE SYRUP ORAL 250 mg\u002F5mL 200 mL","شربت اتوسوکسیماید ۲۵۰ میلی‌گرم \u002F ۵ میلی‌لیتر ۲۰۰ میلی‌لیتر",{"code":124,"en":125,"fa":126},"52957","ETHOSUXIMIDE SYRUP ORAL 250 mg\u002F5mL 100 mL","شربت اتوسوکسیماید ۲۵۰ میلی‌گرم \u002F ۵ میلی‌لیتر ۱۰۰ میلی‌لیتر",[128],{"source":129,"section":130,"url":131},"darooyab-generic","G-663\u002FEthosuximide","https:\u002F\u002Fwww.darooyab.ir\u002FG-663\u002FEthosuximide",{"kind":133,"refs":134,"id":137},"ANDA",[135],{"source":33,"section":136},"SPL approval \u002F marketing category","ANDA080258",[139,142,146,149,152],{"kind":140,"url":141,"label":137},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=080258",{"kind":143,"url":144,"label":145},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=19c924c2-f558-4c78-9277-2d7e0df2f505","FDA Ethosuximide soln",{"kind":147,"url":148,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa682327.html",{"kind":150,"url":151,"label":103},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N03AD01",{"kind":153,"url":131,"label":8},"darooyab",{"pregnancy":155,"pediatric":164},{"level":156,"text":157,"quote":160,"refs":161},"caution",{"fa":158,"en":159},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","To provide information regarding the effects of in utero exposure to ethosuximide, physicians are advised to recommend that pregnant patients taking ethosuximide enroll in the (NAAED) Pregnancy Registry.",[162],{"source":33,"section":163},"Pregnancy",{"level":156,"text":165,"quote":168,"refs":169},{"fa":166,"en":167},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Safety and effectiveness in pediatric patients below the age of 3 years have not been established.",[170],{"source":33,"section":171},"Pediatric Use",1792115179492]